CA2451288A1 - Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines - Google Patents

Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines Download PDF

Info

Publication number
CA2451288A1
CA2451288A1 CA002451288A CA2451288A CA2451288A1 CA 2451288 A1 CA2451288 A1 CA 2451288A1 CA 002451288 A CA002451288 A CA 002451288A CA 2451288 A CA2451288 A CA 2451288A CA 2451288 A1 CA2451288 A1 CA 2451288A1
Authority
CA
Canada
Prior art keywords
methyl
alkyl
pharmaceutically acceptable
thienyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002451288A
Other languages
English (en)
French (fr)
Inventor
David W. Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2451288A1 publication Critical patent/CA2451288A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002451288A 2001-07-31 2002-07-29 Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines Abandoned CA2451288A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30908401P 2001-07-31 2001-07-31
US60/309,084 2001-07-31
PCT/US2002/021301 WO2003011289A1 (en) 2001-07-31 2002-07-29 Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines

Publications (1)

Publication Number Publication Date
CA2451288A1 true CA2451288A1 (en) 2003-02-13

Family

ID=23196615

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002451288A Abandoned CA2451288A1 (en) 2001-07-31 2002-07-29 Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines

Country Status (7)

Country Link
US (1) US20030087938A1 (cg-RX-API-DMAC7.html)
EP (1) EP1411934A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004538305A (cg-RX-API-DMAC7.html)
BR (1) BR0211533A (cg-RX-API-DMAC7.html)
CA (1) CA2451288A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000418A (cg-RX-API-DMAC7.html)
WO (1) WO2003011289A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063048A2 (en) * 2004-12-06 2006-06-15 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
PL2131841T3 (pl) * 2007-01-30 2013-03-29 Avigen Inc Sposoby leczenia bólu ostrego
US20080287402A1 (en) * 2007-05-03 2008-11-20 Johnson Kirk W Use of a glial attenuator to prevent amplified pain responses caused by glial priming

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035511A (en) * 1976-05-06 1977-07-12 Massachusetts Institute Of Technology Process for promoting analgesia
US4596807A (en) * 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5250572A (en) * 1990-03-29 1993-10-05 Eli Lilly And Company (R)-norfluoxetine in method for occupying serotonin IC receptors
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
AU746887B2 (en) * 1998-09-15 2002-05-02 Eli Lilly And Company Treatment of persistent pain
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use

Also Published As

Publication number Publication date
EP1411934A1 (en) 2004-04-28
MXPA04000418A (es) 2004-03-18
JP2004538305A (ja) 2004-12-24
US20030087938A1 (en) 2003-05-08
BR0211533A (pt) 2004-07-13
WO2003011289A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
EP0538422B1 (en) New use of diphenylbutylpiperazinecarboxamides in the treatment of substance disorders
RU2181287C2 (ru) Комбинация, фармацевтическая композиция и способ лечения пациентов, страдающих депрессией
HU224619B1 (hu) Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására
CA1157379A (en) Method of preparation of pharmaceutical composition for treating peripheral orthostatic hypotention
KR20030016230A (ko) 중독성 질환 치료용 프라미펙솔의 용도
BRPI0609952A2 (pt) métodos para modular a função da bexiga
US8461146B2 (en) Pharmaceutical composition for the treatment of premature ejaculation
AU2019382168A1 (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US4279909A (en) Antiallergic method
US20030087938A1 (en) Treatment of chronic pain with 3-heterocycloxy-and 3-cycloalkyloxy-3-phenylpropanamines
KR100761774B1 (ko) 프라미펙솔의 하지 불안 증후군 치료 용도
US20030087965A1 (en) Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
US6194466B1 (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
US4303659A (en) Schistosomicidal compositions
US4145421A (en) Treating spastic conditions
US4795759A (en) Use of dibenz(CD,F)indoles
EP0488041A2 (en) A pharmaceutical composition for cytomegalovirus infection
CA2015336A1 (en) Imidazodiazepines for the treatment of neurological symptoms
EP0238765B1 (fr) Utilisation du 2,2-Diphénoxy-N,N-diméthylaminoéthane pour l'amélioration de l'oxygénation cérébrale
RU2093149C1 (ru) Фармацевтическая композиция для лечения или профилактики гипертонии, связанной с тучностью
US6162833A (en) Photostable aqueous solution comprising benzyl alcohol derivatives
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
JPH02282328A (ja) 陽性の筋変力作用を有する医薬組成物及びその製造方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued